TR200000864T2 - HIV-1 tat ve/veya nef proteinleri içeren füzyon proteinleri - Google Patents

HIV-1 tat ve/veya nef proteinleri içeren füzyon proteinleri

Info

Publication number
TR200000864T2
TR200000864T2 TR2000/00864T TR200000864T TR200000864T2 TR 200000864 T2 TR200000864 T2 TR 200000864T2 TR 2000/00864 T TR2000/00864 T TR 2000/00864T TR 200000864 T TR200000864 T TR 200000864T TR 200000864 T2 TR200000864 T2 TR 200000864T2
Authority
TR
Turkey
Prior art keywords
derivative
protein
hiv
proteins
neph
Prior art date
Application number
TR2000/00864T
Other languages
English (en)
Inventor
Bruck Claudine
Andre Georges Godart Stephane
Marchand Martine
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000864(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR200000864T2 publication Critical patent/TR200000864T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bulus (a)-(i) bir füzyon ortagina veya (ii) bir HIV Nef proteini veya bunun bir türevine bagli bir HIV Tat proteini veya bunun bir türevi; veya (b)-(i) bir füzyon ortagina veya (ii) bir HIV Tat proteini veya bunun bir türevine bagli bir HIV Nef proteini veya bunun bir türevi; veya (c) bir HIV Tat proteini veya bunun bir türevine ve bir füzyon ortagina bagli bir HIV Nef proteini getirir. Buna ilaveten bulus, böyle bir protein kodlayan bir nükleik asitle, Pichia Pastoris gibi, adi geçen nükleik asitle transforme edilmis bir konak hücre temin eder.
TR2000/00864T 1997-09-26 1998-09-17 HIV-1 tat ve/veya nef proteinleri içeren füzyon proteinleri TR200000864T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine

Publications (1)

Publication Number Publication Date
TR200000864T2 true TR200000864T2 (tr) 2000-08-21

Family

ID=10819735

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00864T TR200000864T2 (tr) 1997-09-26 1998-09-17 HIV-1 tat ve/veya nef proteinleri içeren füzyon proteinleri

Country Status (28)

Country Link
EP (1) EP1015596B2 (tr)
JP (2) JP2001518300A (tr)
KR (1) KR100554487B1 (tr)
CN (1) CN1188519C (tr)
AR (2) AR017147A1 (tr)
AT (1) ATE338128T1 (tr)
AU (1) AU746564B2 (tr)
BR (1) BR9812547A (tr)
CA (1) CA2305013C (tr)
CO (1) CO4810339A1 (tr)
CZ (1) CZ302878B6 (tr)
DE (1) DE69835756T3 (tr)
DK (1) DK1015596T4 (tr)
ES (1) ES2272012T5 (tr)
GB (1) GB9720585D0 (tr)
HK (1) HK1030431A1 (tr)
HU (1) HUP0004896A3 (tr)
IL (1) IL135102A0 (tr)
NO (2) NO328824B1 (tr)
NZ (1) NZ503482A (tr)
PL (1) PL195243B1 (tr)
PT (1) PT1015596E (tr)
SA (1) SA98190877B1 (tr)
SI (1) SI1015596T2 (tr)
TR (1) TR200000864T2 (tr)
TW (1) TW499436B (tr)
WO (1) WO1999016884A1 (tr)
ZA (1) ZA988789B (tr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
CA2363118A1 (en) * 1999-02-25 2000-08-31 Smithkline Beecham Biologicals S.A. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
JP2002541786A (ja) * 1999-04-12 2002-12-10 モデックス テラピューティク ソシエテ アノニム 遺伝子治療における使用のための一過性不死化細胞
ATE306938T1 (de) * 1999-06-29 2005-11-15 Glaxosmithkline Biolog Sa Verwendung von cpg als adjuvans für hivimpstoff
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CN1326873C (zh) * 2000-01-31 2007-07-18 史密丝克莱恩比彻姆生物有限公司 用于hiv预防或治疗性免疫的疫苗
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
HU230488B1 (hu) 2001-11-21 2016-08-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
NZ536499A (en) 2002-05-16 2008-04-30 Bavarian Nordic As Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
WO2005090968A1 (en) 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
IL286053B2 (en) * 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
BRPI0819774A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
SI2220241T1 (sl) 2007-11-28 2017-02-28 The Trustees Of The University Of Pennsylvania Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
KR20170078862A (ko) 2008-05-16 2017-07-07 타이가 바이오테크놀로지스, 인코포레이티드 항체 및 그 제조 방법
CA2731767C (en) 2008-07-21 2016-12-06 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
EP3916010A1 (en) 2008-08-28 2021-12-01 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same and methods of identifying agents that modulate myc
JP5809978B2 (ja) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
EP2643465B1 (en) 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Subfamily e simian adenovirus a1321 and uses thereof
WO2012124998A2 (ko) * 2011-03-15 2012-09-20 연세대학교 산학협력단 바이오핀
SG11201407343XA (en) 2012-05-18 2014-12-30 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014012090A1 (en) 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
EP3868387A1 (en) 2012-07-20 2021-08-25 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CA2926221A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
MX365658B (es) 2014-05-13 2019-06-10 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
JP6886406B2 (ja) * 2015-04-16 2021-06-16 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR20240011714A (ko) 2021-04-27 2024-01-26 제너레이션 바이오 컴퍼니 치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
DK0656950T3 (da) * 1992-08-21 1999-07-19 Biogen Inc TAT-afledte transportpolypeptider
ATE302854T1 (de) * 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
JPH11501310A (ja) * 1995-03-08 1999-02-02 ネオバック レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
JP2009213492A (ja) 2009-09-24
HUP0004896A3 (en) 2003-05-28
DK1015596T4 (da) 2010-07-12
JP2001518300A (ja) 2001-10-16
CZ302878B6 (cs) 2012-01-04
CA2305013C (en) 2008-04-08
DE69835756T2 (de) 2007-09-13
ZA988789B (en) 2000-03-29
CN1279718A (zh) 2001-01-10
KR20010024287A (ko) 2001-03-26
KR100554487B1 (ko) 2006-03-03
GB9720585D0 (en) 1997-11-26
DK1015596T3 (da) 2007-01-02
NO328824B1 (no) 2010-05-25
ES2272012T3 (es) 2007-04-16
CA2305013A1 (en) 1999-04-08
AR080331A2 (es) 2012-03-28
WO1999016884A1 (en) 1999-04-08
SI1015596T1 (sl) 2007-02-28
EP1015596B1 (en) 2006-08-30
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
PL195243B1 (pl) 2007-08-31
BR9812547A (pt) 2000-07-25
CZ20001091A3 (cs) 2000-09-13
SA98190877B1 (ar) 2006-09-10
NO20001508L (no) 2000-05-18
NZ503482A (en) 2001-09-28
ES2272012T5 (es) 2010-07-06
AU746564B2 (en) 2002-05-02
AR017147A1 (es) 2001-08-22
PL339432A1 (en) 2000-12-18
DE69835756D1 (de) 2006-10-12
CN1188519C (zh) 2005-02-09
HUP0004896A1 (hu) 2001-04-28
DE69835756T3 (de) 2010-09-30
EP1015596A1 (en) 2000-07-05
IL135102A0 (en) 2001-05-20
NO20076467L (no) 2000-05-18
EP1015596B2 (en) 2010-04-14
AU1025599A (en) 1999-04-23
SI1015596T2 (sl) 2010-07-30
TW499436B (en) 2002-08-21
CO4810339A1 (es) 1999-06-30
ATE338128T1 (de) 2006-09-15
HK1030431A1 (en) 2001-05-04

Similar Documents

Publication Publication Date Title
TR200000864T2 (tr) HIV-1 tat ve/veya nef proteinleri içeren füzyon proteinleri
DE60238541D1 (de) Modifizierte transferrin-fusionsproteine
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
BR0314093A (pt) Proteìnas de fusão de transferrina modificada-anticorpo
ATE544776T1 (de) Chimäre dna-bindeproteine
DE69838171D1 (de) Immunstimulierende chelatkomplexe
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
DK1346034T3 (da) von Willebrand-faktor (vWF) spaltende protease-polypeptid, nukleinsyre kodende for polypeptidet og anvendelse af polypeptidet
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
ATE260092T1 (de) 5-aminolävulinsäure-nanoemulsion
WO2001059094A3 (en) Method of regulating transcription in a cell by altering remodeling of cromatin
DE69802389D1 (de) Verbindungen verwendbar als effektoren von neuroexcitatorischen aminosäure-empfindlichen rezeptoren des zentralnervensystems, ihre herstellung and ihre biologischen verwendungen
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
TR200003323T2 (tr) Geniş-tesir sahalı mantar önleyiciler olarak suda eriyebilir azoller
ATE452650T1 (de) Transferrin-fusionsproteinbibliotheken
DK1012256T3 (da) Rekombinante fusionsproteiner på basis af ribosom-inaktiverende proteiner fra misteltenen Viscum album
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E
SE0101519D0 (sv) Nucleic ACID
WO2005099745A3 (en) Gcp-170 fusion proteins and uses thereof
DE60236143D1 (de) Gewebe transglutaminase
DE50113417D1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
ES1020627U (es) Modulo de alambre apilable.